Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Pharmaceutics|February 25, 2023
Recent Advances in the Development of Nanodelivery Systems Targeting the TRAIL Death Receptor PathwayAnne V Yagolovich, Marine E Gasparian, Dmitry A Dolgikh
Frontiers in Cell and Developmental Biology|October 18, 2021
Death Receptors DR4 and DR5 Undergo Spontaneous and Ligand-Mediated Endocytosis and Recycling Regardless of the Sensitivity of Cancer Cells to TRAILArtem A Artykov, Anne V Yagolovich, Dmitry A Dolgikh, et al.
Frontiers in Cell and Developmental Biology|March 3, 2022
Corrigendum: Death Receptors DR4 and DR5 Undergo Spontaneous and Ligand-Mediated Endocytosis and Recycling Regardless of the Sensitivity of Cancer Cells to TRAILArtem A Artykov, Anne V Yagolovich, Dmitry A Dolgikh, et al.
International Journal of Molecular Sciences|June 10, 2022
Optimized Heterologous Expression and Efficient Purification of a New TRAIL-Based Antitumor Fusion Protein SRH-DR5-B with Dual VEGFR2 and DR5 Receptor SpecificityAnne V Yagolovich, Artem A Artykov, Alina A Isakova, et al.
Biotechnology Letters|July 5, 2007
Overexpression and refolding of thioredoxin/TRAIL fusion from inclusion bodies and further purification of TRAIL after cleavage by enteropeptidaseMarine E Gasparian, Valeriy G Ostapchenko, Anne V Yagolovich, et al.
Apoptosis : an International Journal on Programmed Cell Death|May 5, 2009
Generation of new TRAIL mutants DR5-A and DR5-B with improved selectivity to death receptor 5Marine E Gasparian, Boris V Chernyak, Dmitry A Dolgikh, et al.
Biochemistry. Biokhimiia|November 10, 2024
Glioblastoma Sensitization to Therapeutic Effects by Glutamine Deprivation Depends on Cellular Phenotype and MetabolismAlina A Isakova, Irina N Druzhkova, Artem M Mozherov, et al.
Translational Oncology|April 1, 2020
Genetically Modified DR5-Specific TRAIL Variant DR5-B Revealed Dual Antitumor and Protumoral Effect in Colon Cancer Xenografts and an Improved Pharmacokinetic ProfileAnne V Yagolovich, Artem A Artykov, Tatiana A Karmakova, et al.
Biochemistry. Biokhimiia|October 9, 2025
Novel Fusion Protein Based on DR5-Specific TRAIL Variant with Enhanced Antitumor PropertiesAnne V Yagolovich, Alina A Isakova, Ekaterina V Kukovyakina, et al.
Medical Oncology (Northwood, London, England)|November 17, 2025
Temozolomide-induced senescent glioblastoma cells acquire sensitivity to TRAIL death receptor 5-mediated apoptosisAlina A Isakova, Diana V Mazur, Nadezhda V Antipova, et al.
Pageof 2